Navigation Links
Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
Date:10/8/2007

- Data Presented at the 132nd Annual Meeting of the American Neurological

Association in Washington, D.C. -

ATLANTA, Oct. 8 /PRNewswire/ -- UCB, Inc. presented results from two Phase III pivotal trials and one open-label extension trial of rotigotine transdermal system for the treatment of moderate-to-severe restless legs syndrome (RLS). These rotigotine data showed significant drops in RLS symptoms, including changes of up to 8 points over placebo using the International Restless Legs Syndrome Study Group Rating Scale (IRLS) and a reduction in disease severity over a two-year period.

"Given the strong efficacy and tolerability seen to date, rotigotine, if approved, would provide a new and valuable alternative for many patients negatively impacted by the symptoms of moderate-to-severe RLS," said Wayne Hening, M.D., a lead study investigator and Assistant Clinical Professor of Neurology at the Robert Wood Johnson Medical School.

In the two six-month, double-blind, placebo-controlled trials, rotigotine produced clinically relevant and statistically significant reductions in RLS symptoms compared to placebo and was generally well-tolerated. An additional presentation highlighted a two-year interim analysis of a long-term, open- label extension of rotigotine for moderate-to-severe RLS, representing some of the longest safety follow-up information for a dopamine agonist in RLS to date.

In these studies, the efficacy of rotigotine was evaluated by monitoring several clinician-administered scales including the IRLS, the Clinical Global Impressions (CGI) and the Restless Leg Syndrome-6 (RLS-6). The IRLS scale measures the severity and frequency of RLS symptoms and the degree to which they affect sleep and daily life (IRLS: 0 = no symptoms and 40 = very severe symptoms). The CGI scale measures the general severity of an illness, clinical improvement or efficacy of treatment parameters. On the RLS-6 scale, patients rate the
'/>"/>

SOURCE UCB, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
2. NuPathe Reports Positive Phase One Results for NP101 Transdermal Therapy for Acute Migraine
3. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
4. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
5. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
6. When Volume Matters, Immunoassay Systems Deliver
7. Genetic Analysis Systems Enter the Clinical Mainstream
8. New Quality Control Systems for Every Laboratory Application
9. Immunoassay Systems - Your Laboratory Workhorse
10. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
11. Researchers Discover Method for Identifying How Cancer Evades the Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)...  Three-month paliperidone palmitate, an investigational atypical antipsychotic, ... in patients with schizophrenia, according to a new ... the Journal of the American Medical ... of the study served as the basis for ... three-month paliperidone palmitate injection to treat schizophrenia in ...
(Date:3/27/2015)... 27, 2015 BioCorRx, Inc. ( ... California is a healthcare solutions organization, which focuses ... at $22 billion in the U.S. alone. The Company created ... Naltrexone in a specially compounded form for outpatient surgical implantation. ... and New Zealand ) to the ...
(Date:3/27/2015)... 2015 Across the global healthcare landscape, the ... clinical development, market education, and regulatory compliance. As emerging ... function is expected to increase in prominence and follow ... According to research by benchmarking firm, Best Practices, LLC, ... to Medical Affairs. Among companies in India ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
... Aug. 16 Endologix, Inc. (Nasdaq: ELGX ... announced today that it has entered into a development ... for its balloon expandable stent technology. Evasc is a ... patented stent is made from cobalt chromium and is ...
... PRA International, a leading Clinical Research Organization, will host ... drug development on 24 August 2010 at 11:30 am ... PRA,s Scientific Affairs unit, will be the presenter. ... of the expensive failures that pharmaceutical companies experience during ...
Cached Medicine Technology:Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology 2Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology 3PRA International Hosts Audio Conference on CV Drug Development 2
(Date:3/29/2015)... (PRWEB) March 29, 2015 The ... ( http://www.testosteronelawsuithub.com/ ) pending in the U.S. District ... litigation’s next Case Management Conference for April 21st ... meeting will address the progress of product liability ... experienced heart attacks, strokes and other cardiovascular complications ...
(Date:3/29/2015)... March 29, 2015 At this ... platform provides basic health information around medical conditions ... discuss these challenges as well as helping them ... addresses six medical conditions using evidenced based information ... engage in conversations around them., ...
(Date:3/29/2015)... Ore. (PRWEB) March 29, 2015 Youth ... Marion counties in Oregon to assess the feasibility of ... with emotional and behavioral problems and their families. , ... to select participants that will be provided technical assistance ... Oregon counties join six other national awardees chosen by ...
(Date:3/29/2015)... 29, 2015 Final Cut Pro ... from Pixel Film Studios, entitled TranSports. , “TranSports ... for Final Cut Pro X,” said Christiana Austin, CEO ... tools needed to effortlessly transition using this cool sports ... new and uniquely styled transition pack for Final Cut ...
(Date:3/29/2015)... TN (PRWEB) March 29, 2015 North ... several PT Online Continuing Education Courses . ... 10.0 hours of CME - TPTA, approval # 56399TX ... the evaluation of the shoulder complex - 10.5 hours ... Approved #56400TX , Examination and Treatment of the SI ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 3Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2
... Findings of a recent study suggests hunger may be ... researchers // studied 16 men who agreed to skip breakfast. ... evening. Participants were asked to consume sugary, salty or bitter ... not swallow the drinks, but instead spit them out after ...
... with chemo-resistant leukemia, a new drug is showing promising ... experimenting with bacteria-based recombinant immunotoxins. An immunotoxin is bioengineered ... part of the antibodies that are commonly used to ... encouraging results in a phase II study. ,Researchers ...
... Latest research shows the chickenpox vaccine loses some ... vaccination.// Parents are encouraged to vaccinate their children ... Consequently, researchers were prompted to further investigate the ... individuals. ,Researchers studied nearly 350 children ...
... common form of cancer in the United States. According to ... against colon cancer. In addition, soy protein may help minimize ... fed five different diets to female mice and followed their ... the effects of specific ingredients. Diet one contained milk protein, ...
... get up and get moving. Breast cancer survivors ... body esteem and better mood than sedentary breast ... ,Researchers compared 40 women who said they regularly ... cancer survivors. Regular exercisers reported significantly more positive ...
... depression may have an increased risk of heart disease ... than 93,600 older women who participated in the Women's ... long-term program designed to determine how biological and lifestyle ... and other health conditions. For this study, participants were ...
Cached Medicine News:
Blood sedimentation rate analysis...
Blood sedimentation rate analysis...
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
The CA-500 series quickly and accurately measures up to 5 coagulation parameters. It is the analyzer of choice for low to mid volume laboratories, or as a backup to larger coagulation analyzers....
Medicine Products: